Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies

被引:23
作者
Hernandez, Carlos [1 ]
Arasanz, Hugo [1 ,2 ]
Chocarro, Luisa [1 ]
Bocanegra, Ana [1 ]
Zuazo, Miren [1 ]
Fernandez-Hinojal, Gonzalo [2 ]
Blanco, Ester [1 ]
Vera, Ruth [2 ]
Escors, David [1 ]
Kochan, Grazyna [1 ]
机构
[1] IdISNA, UPNA, Biomed Res Ctr Navarrabiomed, Oncoimmunol Grp, Irunlarrea 3, Pamplona 31008, Spain
[2] IdISNA, Complejo Hosp Navarra, Dept Oncol, Irunlarrea 3, Pamplona 31008, Spain
关键词
immunotherapy; immune checkpoint inhibitors; systemic blood subsets; CD4(+); CD8(+); MDSCs; MISMATCH REPAIR DEFICIENCY; MEMORY T-CELLS; PERIPHERAL-BLOOD; PD-1; BLOCKADE; CLINICAL-SIGNIFICANCE; IPILIMUMAB TREATMENT; PREDICTS RESPONSE; HYPERPROGRESSION; LYMPHOCYTES; INCREASES;
D O I
10.3390/ijms21072411
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use for the treatment of numerous cancers. However, approximately only a third of the patients benefit from ICI therapies. Many efforts have been made for the identification of biomarkers allowing patient stratification into potential responders and progressors before the start of ICI therapies or for monitoring responses during treatment. While much attention is centered on biomarkers from the tumor microenvironment, in many cases biopsies are not available. The identification of systemic immune cell subsets that correlate with responses could provide promising biomarkers. Some of them have been reported to influence the response to ICI therapies, such as proliferation and activation status of CD8 and CD4 T cells, the expression of immune checkpoints in peripheral blood cells and the relative numbers of immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells. In addition, the profile of soluble factors in plasma samples could be associated to response or tumor progression. Here we will review the cellular subsets associated to response or progression in different studies and discuss their accuracy in diagnosis.
引用
收藏
页数:13
相关论文
共 63 条
  • [11] Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
    Gebhardt, Christoffer
    Sevko, Alexandra
    Jiang, Huanhuan
    Lichtenberger, Ramtin
    Reith, Maike
    Tarnanidis, Kathrin
    Holland-Letz, Tim
    Umansky, Ludmila
    Beckhove, Philipp
    Sucker, Antje
    Schadendorf, Dirk
    Utikal, Jochen
    Umansky, Viktor
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (24) : 5453 - 5459
  • [12] Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
    Groth, Christopher
    Hu, Xiaoying
    Weber, Rebekka
    Fleming, Viktor
    Altevogt, Peter
    Utikal, Jochen
    Umansky, Viktor
    [J]. BRITISH JOURNAL OF CANCER, 2019, 120 (01) : 16 - 25
  • [13] Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
    Hamanishi, Junzo
    Mandai, Masaki
    Iwasaki, Masashi
    Okazaki, Taku
    Tanaka, Yoshimasa
    Yamaguchi, Ken
    Higuchi, Toshihiro
    Yagi, Haruhiko
    Takakura, Kenji
    Minato, Nagahiro
    Honjo, Tasuku
    Fujii, Shingo
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (09) : 3360 - 3365
  • [14] TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer
    Han, Jiefei
    Duan, Jianchun
    Bai, Hua
    Wang, Yuqi
    Wan, Rui
    Wang, Xin
    Chen, Si
    Tian, Yanhua
    Wang, Di
    Fei, Kailun
    Yao, Zhuoran
    Wang, Shuhang
    Lu, Zhimin
    Wang, Zhijie
    Wang, Jie
    [J]. CANCER IMMUNOLOGY RESEARCH, 2020, 8 (01) : 146 - 154
  • [15] A phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)
    Hazama, Shoichi
    Nakamura, Yusuke
    Tanaka, Hiroaki
    Hirakawa, Kosei
    Tahara, Ko
    Shimizu, Ryoichi
    Ozasa, Hiroaki
    Etoh, Ryuichi
    Sugiura, Fumiaki
    Okuno, Kiyotaka
    Furuya, Takumi
    Nishimura, Taku
    Sakata, Koichiro
    Yoshimatsu, Kazuhiko
    Takenouchi, Hiroko
    Tsunedomi, Ryouichi
    Inoue, Yuka
    Kanekiyo, Shinsuke
    Shindo, Yoshitaro
    Suzuki, Nobuaki
    Yoshino, Shigefumi
    Shinozaki, Hirokazu
    Kamiya, Akira
    Furukawa, Hiroyuki
    Yamanaka, Takeharu
    Fujita, Tomonobu
    Kawakami, Yutaka
    Oka, Masaaki
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
  • [16] T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
    Huang, Alexander C.
    Postow, Michael A.
    Orlowski, Robert J.
    Mick, Rosemarie
    Bengsch, Bertram
    Manne, Sasikanth
    Xu, Wei
    Harmon, Shannon
    Giles, Josephine R.
    Wenz, Brandon
    Adamow, Matthew
    Kuk, Deborah
    Panageas, Katherine S.
    Carrera, Cristina
    Wong, Phillip
    Quagliarello, Felix
    Wubbenhorst, Bradley
    D'Andrea, Kurt
    Pauken, Kristen E.
    Herati, Ramin S.
    Staupe, Ryan P.
    Schenkel, Jason M.
    McGettigan, Suzanne
    Kothari, Shawn
    George, Sangeeth M.
    Vonderheide, Robert H.
    Amaravadi, Ravi K.
    Karakousis, Giorgos C. .
    Schuchter, Lynn M.
    Xu, Xiaowei
    Nathanson, Katherine L.
    Wolchok, Jedd D.
    Gangadhar, Tara C.
    Wherry, E. John
    [J]. NATURE, 2017, 545 (7652) : 60 - +
  • [17] T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
    Hui, Enfu
    Cheung, Jeanne
    Zhu, Jing
    Su, Xiaolei
    Taylor, Marcus J.
    Wallweber, Heidi A.
    Sasmal, Dibyendu K.
    Huang, Jun
    Kim, Jeong M.
    Mellman, Ira
    Vale, Ronald D.
    [J]. SCIENCE, 2017, 355 (6332) : 1428 - +
  • [18] Predictors of responses to immune checkpoint blockade in advanced melanoma
    Jacquelot, N.
    Roberti, M. P.
    Enot, D. P.
    Rusakiewicz, S.
    Ternes, N.
    Jegou, S.
    Woods, D. M.
    Sodre, A. L.
    Hansen, M.
    Meirow, Y.
    Sade-Feldman, M.
    Burra, A.
    Kwek, S. S.
    Flament, C.
    Messaoudene, M.
    Duong, C. P. M.
    Chen, L.
    Kwon, B. S.
    Anderson, A. C.
    Kuchroo, V. K.
    Weide, B.
    Aubin, F.
    Borg, C.
    Dalle, S.
    Beatrix, O.
    Ayyoub, M.
    Balme, B.
    Tomasic, G.
    Di Giacomo, A. M.
    Maio, M.
    Schadendorf, D.
    Melero, I.
    Dreno, B.
    Khammari, A.
    Dummer, R.
    Levesque, M.
    Koguchi, Y.
    Fong, L.
    Lotem, M.
    Baniyash, M.
    Schmidt, H.
    Svane, I. M.
    Kroemer, G.
    Marabelle, A.
    Michiels, S.
    Cavalcanti, A.
    Smyth, M. J.
    Weber, S.
    Eggermont, A. M.
    Zitvogel, L.
    [J]. NATURE COMMUNICATIONS, 2017, 8
  • [19] CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
    Kagamu, Hiroshi
    Kitano, Shigehisa
    Yamaguchi, Ou
    Yoshimura, Kenichi
    Horimoto, Katsuhisa
    Kitazawa, Masashi
    Fukui, Kazuhiko
    Shiono, Ayako
    Mouri, Atsuhito
    Nishihara, Fuyumi
    Miura, Yu
    Hashimoto, Kosuke
    Murayama, Yoshitake
    Kaira, Kyoichi
    Kobayashi, Kunihiko
    [J]. CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 334 - 344
  • [20] PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
    Kamada, Takahiro
    Togashi, Yosuke
    Tay, Christopher
    Ha, Danbee
    Sasaki, Akinori
    Nakamura, Yoshiaki
    Sato, Eiichi
    Fukuoka, Shota
    Tada, Yasuko
    Tanaka, Atsushi
    Morikawa, Hiromasa
    Kawazoe, Akihito
    Kinoshita, Takahiro
    Shitara, Kohei
    Sakaguchi, Shimon
    Nishikawa, Hiroyoshi
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (20) : 9999 - 10008